Minimal exposure of lipid II cycle intermediates triggers cell wall antibiotic resistance

Hannah Piepenbreier, Angelika Diehl, Georg Fritz

Research output: Contribution to journalArticle

Abstract

Cell wall antibiotics are crucial for combatting the emerging wave of resistant bacteria. Yet, our understanding of antibiotic action is limited, as many strains devoid of all resistance determinants display far higher antibiotic tolerance in vivo than suggested by the antibiotic-target binding affinity in vitro. To resolve this conflict, here we develop a comprehensive theory for the bacterial cell wall biosynthetic pathway and study its perturbation by antibiotics. We find that the closed-loop architecture of the lipid II cycle of wall biosynthesis features a highly asymmetric distribution of pathway intermediates, and show that antibiotic tolerance scales inversely with the abundance of the targeted pathway intermediate. We formalize this principle of minimal target exposure as intrinsic resistance mechanism and predict how cooperative drug-target interactions can mitigate resistance. The theory accurately predicts the in vivo efficacy for various cell wall antibiotics in different Gram-positive bacteria and contributes to a systems-level understanding of antibiotic action.

Original languageEnglish
Article number2733
JournalNature Communications
Volume10
Issue number1
DOIs
Publication statusPublished - 21 Jun 2019
Externally publishedYes

Fingerprint

antibiotics
Microbial Drug Resistance
Cell Wall
lipids
actuators
Cells
Anti-Bacterial Agents
cycles
bacteria
Bacteria
biosynthesis
muramyl-NAc-(pentapeptide)pyrophosphoryl-undecaprenol
Biosynthesis
Biosynthetic Pathways
Gram-Positive Bacteria
Drug Interactions
determinants
affinity
emerging
drugs

Cite this

@article{f35927ccfa514e29a0dff6e64343ff5c,
title = "Minimal exposure of lipid II cycle intermediates triggers cell wall antibiotic resistance",
abstract = "Cell wall antibiotics are crucial for combatting the emerging wave of resistant bacteria. Yet, our understanding of antibiotic action is limited, as many strains devoid of all resistance determinants display far higher antibiotic tolerance in vivo than suggested by the antibiotic-target binding affinity in vitro. To resolve this conflict, here we develop a comprehensive theory for the bacterial cell wall biosynthetic pathway and study its perturbation by antibiotics. We find that the closed-loop architecture of the lipid II cycle of wall biosynthesis features a highly asymmetric distribution of pathway intermediates, and show that antibiotic tolerance scales inversely with the abundance of the targeted pathway intermediate. We formalize this principle of minimal target exposure as intrinsic resistance mechanism and predict how cooperative drug-target interactions can mitigate resistance. The theory accurately predicts the in vivo efficacy for various cell wall antibiotics in different Gram-positive bacteria and contributes to a systems-level understanding of antibiotic action.",
author = "Hannah Piepenbreier and Angelika Diehl and Georg Fritz",
year = "2019",
month = "6",
day = "21",
doi = "10.1038/s41467-019-10673-4",
language = "English",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group - Macmillan Publishers",
number = "1",

}

Minimal exposure of lipid II cycle intermediates triggers cell wall antibiotic resistance. / Piepenbreier, Hannah; Diehl, Angelika; Fritz, Georg.

In: Nature Communications, Vol. 10, No. 1, 2733, 21.06.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Minimal exposure of lipid II cycle intermediates triggers cell wall antibiotic resistance

AU - Piepenbreier, Hannah

AU - Diehl, Angelika

AU - Fritz, Georg

PY - 2019/6/21

Y1 - 2019/6/21

N2 - Cell wall antibiotics are crucial for combatting the emerging wave of resistant bacteria. Yet, our understanding of antibiotic action is limited, as many strains devoid of all resistance determinants display far higher antibiotic tolerance in vivo than suggested by the antibiotic-target binding affinity in vitro. To resolve this conflict, here we develop a comprehensive theory for the bacterial cell wall biosynthetic pathway and study its perturbation by antibiotics. We find that the closed-loop architecture of the lipid II cycle of wall biosynthesis features a highly asymmetric distribution of pathway intermediates, and show that antibiotic tolerance scales inversely with the abundance of the targeted pathway intermediate. We formalize this principle of minimal target exposure as intrinsic resistance mechanism and predict how cooperative drug-target interactions can mitigate resistance. The theory accurately predicts the in vivo efficacy for various cell wall antibiotics in different Gram-positive bacteria and contributes to a systems-level understanding of antibiotic action.

AB - Cell wall antibiotics are crucial for combatting the emerging wave of resistant bacteria. Yet, our understanding of antibiotic action is limited, as many strains devoid of all resistance determinants display far higher antibiotic tolerance in vivo than suggested by the antibiotic-target binding affinity in vitro. To resolve this conflict, here we develop a comprehensive theory for the bacterial cell wall biosynthetic pathway and study its perturbation by antibiotics. We find that the closed-loop architecture of the lipid II cycle of wall biosynthesis features a highly asymmetric distribution of pathway intermediates, and show that antibiotic tolerance scales inversely with the abundance of the targeted pathway intermediate. We formalize this principle of minimal target exposure as intrinsic resistance mechanism and predict how cooperative drug-target interactions can mitigate resistance. The theory accurately predicts the in vivo efficacy for various cell wall antibiotics in different Gram-positive bacteria and contributes to a systems-level understanding of antibiotic action.

UR - http://www.scopus.com/inward/record.url?scp=85067613345&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-10673-4

DO - 10.1038/s41467-019-10673-4

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 2733

ER -